Literature DB >> 14986252

Inactivated influenza virus vaccines in children.

Frederick L Ruben1.   

Abstract

Healthy children aged < or =2 years have hospitalization rates during influenza periods 12 times those of older children and comparable to rates in the elderly population. In 2003, killed influenza vaccines were "recommended" for children with high-risk conditions and were "encouraged" for children aged 6-23 months. Studies involving several thousand children show that split-virus vaccines are safe and immunogenic in healthy children aged > or =6 months and in high-risk children. In children aged < or =9 years, 2 doses of vaccine are required initially to achieve maximum protection. Studies of children aged 6 months to 15 years show vaccine efficacies of 31%-91% against influenza A and 45% against influenza B. Among children attending day care, a reduction in the rate of acute otitis media of 32%-36% was demonstrated. Studies suggest that use of killed vaccines among children is cost-saving. In conclusion, the data show that killed influenza vaccines in children are safe, immunogenic, effective, and potentially cost-saving.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14986252     DOI: 10.1086/382883

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  17 in total

Review 1.  Pediatric cardiology for the primary care pediatrician.

Authors:  M Regina Lantin-Hermoso
Journal:  Indian J Pediatr       Date:  2005-06       Impact factor: 1.967

2.  Effect of expanded US recommendations for seasonal influenza vaccination: comparison of two pediatric emergency departments in the United States and Canada.

Authors:  Anne Gatewood Hoen; David L Buckeridge; Katia M L Charland; Kenneth D Mandl; Caroline Quach; John S Brownstein
Journal:  CMAJ       Date:  2011-09-20       Impact factor: 8.262

Review 3.  Effectiveness and safety of seasonal influenza vaccination in children with underlying respiratory diseases and allergy.

Authors:  Jin-Han Kang
Journal:  Korean J Pediatr       Date:  2014-04-30

Review 4.  Influenza burden of illness, diagnosis, treatment, and prevention: what is the evidence in children and where are the gaps?

Authors:  S S S Teo; J S Nguyen-Van-Tam; R Booy
Journal:  Arch Dis Child       Date:  2005-05       Impact factor: 3.791

5.  Immunogenicity and safety of an inactivated trivalent split influenza virus vaccine in young children with recurrent wheezing.

Authors:  E Young Bae; Ui Yoon Choi; Hyo Jin Kwon; Dae Chul Jeong; Jung Woo Rhim; Sang Hyuk Ma; Kyung Il Lee; Jin Han Kang
Journal:  Clin Vaccine Immunol       Date:  2013-03-27

6.  Rituximab-treated patients have a poor response to influenza vaccination.

Authors:  Robert A Eisenberg; Abbas F Jawad; Jean Boyer; Kelly Maurer; Kenyetta McDonald; Eline T Luning Prak; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2012-10-14       Impact factor: 8.317

7.  Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.

Authors:  Natasha B Halasa; Michael A Gerber; Andrea A Berry; Edwin L Anderson; Patricia Winokur; Harry Keyserling; Allison Ross Eckard; Heather Hill; Mark C Wolff; Monica M McNeal; Kathryn M Edwards; David I Bernstein
Journal:  J Pediatric Infect Dis Soc       Date:  2014-06-27       Impact factor: 3.164

8.  Safety and immunogenicity of trivalent inactivated influenza vaccine in infants.

Authors:  Natasha B Halasa; Michael A Gerber; Qingxia Chen; Peter F Wright; Kathryn M Edwards
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

Review 9.  Seasonal inactivated influenza virus vaccines.

Authors:  Robert B Couch
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641

10.  Antibody responses after inactivated influenza vaccine in young children.

Authors:  Peter F Wright; Edith Sannella; Jian R Shi; Yuwei Zhu; Mine R Ikizler; Kathryn M Edwards
Journal:  Pediatr Infect Dis J       Date:  2008-11       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.